取决于DNA的蛋白激酶催化子单元 (DNA-PKcs) 通过调节线粒体碎片化来驱动动血管新生素II诱导的血管改造
Litao Wang1, Lin Wu1, Yuxin Du1
1Department of Cardiology, Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital Fudan University, Shanghai, 200032, China; National Clinical Research Center for Interventional Medicine, Shanghai, 200032, China.
Redox biology
|September 23, 2023
概括
依赖DNA的蛋白激酶催化子单元 (DNA-PKcs) 通过与Drp1相互作用,促进血管重塑和高血压,导致线粒体功能障碍. 向DNA-PKcs可能为心血管疾病提供新的治疗策略.
科学领域:
- 心血管生物学 心血管生物学
- 线粒体生物学 线粒体生物学
- 分子医学是分子医学.
背景情况:
- 取决于DNA的蛋白激酶催化子单元 (DNA-PKcs) 与线粒体功能障碍和心血管疾病有关.
- 在血管素II (Ang II) 诱导的血管改造中,DNA-PKcs的特定作用尚不清楚.
研究的目的:
- 研究DNA-PKcs在Ang II诱导的血管重塑中的作用和机制.
- 探索DNA-PKcs与血管光滑肌细胞 (VSMCs) 中的胺相关蛋白1 (Drp1) 的相互作用.
主要方法:
- 使用了VSMC特定的DNA-PKcs淘汰赛小鼠 (DNA-PKcsΔVSMC) 和野生类型的 littermates.
- 施用Ang II来诱导血管改造和监测血压.
- 通过放松试验评估血管功能,并分析涉及Drp1酸化和线粒体分裂的分子机制.
主要成果:
- 在重塑的大动脉和高血压患者的动脉中观察到细胞质DNA-PKcs的升高.
- DNA-PKcsΔVSMC小鼠在Ang II输液后表现出减弱的血管改造,改善的血管扩张和降低的高血压.
- 安格II诱导了DNA-PKcs与Drp1的相互作用,导致Drp1S616的酸化,线粒体碎片化和活性氧物种 (ROS) 的增加.
结论:
- 细胞质DNA-PKcs通过Drp1相互作用促进线粒体碎片化,加速Ang II诱导的血管重塑.
- 向DNA-PKcs为治疗血管改造和高血压提供了潜在的治疗途径.
相关概念视频
ATP Synthase: Mechanism
14.7K
In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
14.7K
Regulation of Angiogenesis and Blood Supply
2.6K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
MAPK Signaling Cascades
5.6K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.6K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
683
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
683
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
454
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
454


